

Date: 31<sup>st</sup> May, 2025

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
BSE Scrip Code: 533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APLLTD

Dear Sir / Madam,

**Sub: USFDA inspection at Alembic Pharmaceuticals Limited's API - I & II Facility located at Panelav.**

We would like to inform the exchange that the United States Food and Drug Administration (US FDA) has conducted an inspection at our API-I & II Facility located at Panelav from 26<sup>th</sup> May, 2025 to 31<sup>st</sup> May, 2025. This was an un-announced and routine cGMP inspection. The USFDA issued a Form 483 with four observations.

None of the observations are related to data integrity and management believes that they are addressable.

The Company will provide comprehensive response to USFDA for the observations within the stipulated period.

The Company is committed to maintain the highest quality standards and compliance at all times.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

**For Alembic Pharmaceuticals Limited**

**Manisha Saraf**  
**Company Secretary**

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229  
Website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123